Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guang Sun

Showing results (621-630 of 624) with videos related to

Pageof 63
Sort By:
You have reached the last page of results.This site can display upto 624 results.
The Lancet. Infectious Diseases|June 30, 2026
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trialHong-Xing Pan, Zhao-Feng Bi, Yu-Lin Jing, et al.
The Lancet. Infectious Diseases|August 29, 2022
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trialFang-Hui Zhao, Ting Wu, Yue-Mei Hu, et al.
BJU International|April 9, 2019
The status and characteristics of urinary stone composition in ChinaZhangqun Ye, Guohua Zeng, Huan Yang, et al.
Asian Journal of Urology|February 19, 2019
Application of fluorescence <i>in situ</i> hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese populationLiqun Zhou, Kaiwei Yang, Xuesong Li, et al.
Pageof 63

Showing results (621-630 of 624) with videos related to

Sort By:
Pageof 63
You have reached the last page of results.This site can display upto 624 results.
The Lancet. Infectious Diseases|June 30, 2026
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trialHong-Xing Pan, Zhao-Feng Bi, Yu-Lin Jing, et al.
The Lancet. Infectious Diseases|August 29, 2022
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trialFang-Hui Zhao, Ting Wu, Yue-Mei Hu, et al.
BJU International|April 9, 2019
The status and characteristics of urinary stone composition in ChinaZhangqun Ye, Guohua Zeng, Huan Yang, et al.
Asian Journal of Urology|February 19, 2019
Application of fluorescence <i>in situ</i> hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese populationLiqun Zhou, Kaiwei Yang, Xuesong Li, et al.
Pageof 63